The Advanced Renal Cell Carcinoma Pipeline Insight 2023 report by DelveInsight offers a thorough global overview of Advanced Renal Cell Carcinoma treatments, including those already in the market, as well as those in different phases of clinical development. Prominent pharmaceutical firms are dedicated to progressing the Advanced Renal Cell Carcinoma pipeline landscape and fostering the potential growth of Advanced Renal Cell Carcinoma therapeutic advancements.
Key Takeaways from the Advanced Renal Cell Carcinoma Pipeline Report
- DelveInsight’s Advanced Renal Cell Carcinoma pipeline report depicts a robust space with 50+ active players working to develop 60+ pipeline therapies for Advanced Renal Cell Carcinoma treatment.
- The leading companies working in the Advanced Renal Cell Carcinoma market include Merck Sharp & Dohme, Chia Tai Tianqing Pharmaceutical, Hoffmann-La Roche, CoImmune, Infinity Pharmaceuticals, NiKang Therapeutics, Molecure S.A., Daiichi Sankyo, Janux Therapeutics, MedImmune, Eli Lilly and Company, Jiangsu HengRui Medicine Co., Ltd., Allogene Therapeutics, Chongqing Precision Biotech Co., Ltd, Pfizer, Exelixis, BeiGene, Xencor, and others.
- Promising Advanced Renal Cell Carcinoma Pipeline Therapies in the various stages of development include ABT-869, MEDI5752, Axitinib, Lenvatinib, CMN-001, Cabozantinib, Sorafenib, Tivozanib (AV-951), and others.
- December 2023: Pfizer announced a study of Phase 3 clinical trials for Avelumab (MSB0010718C), Axitinib (AG-013736) and Sunitinib. This is a phase 3 randomized trial evaluating the anti-tumor activity and safety of avelumab in combination with axitinib and of sunitinib monotherapy, administered as first-line treatment, in patients with advanced renal cell carcinoma
- July 2023: Hutchmed Medipharma Limited announced a study of Phase 2 & 3 Clinical Trials for fruquintinib+sintilimab, axitinib / everolimus, and fruquintinib. The study consists of two parts, the first part is a randomized, open-label, active-controlled study to evaluate the efficacy and safety of fruquintinib in combination with sintilimab versus axitinib or everolimus montherapy as second-line treatment for locally advanced or metastatic renal cell carcinoma.
- August 2023: MedImmune LLC announced a study of Phase 1 Clinical Trials for MEDI5752, Axitinib, and Lenvatinib. The purpose of this study is to evaluate MEDI5752 in combination with Lenvatinib (or Axitinib), in subjects with advanced renal cell carcinoma.
- August 2023: Bristol-Myers Squibb announced a study of Phase 3 Clinical Trials for Nivolumab, Ipilimumab, and Sunitinib. The purpose of this study is to compare the objective response rate, progression free survival and the overall survival of Nivolumab combined with Ipilimumab to Sunitinib monotherapy in patients with previously untreated Renal Cell Cancer.
Request a sample and discover the recent advances in Advanced Renal Cell Carcinoma Treatment Drugs @ Advanced Renal Cell Carcinoma Pipeline Report
The Advanced Renal Cell Carcinoma pipeline report provides detailed profiles of pipeline assets, a comparative analysis of clinical and non-clinical stage Advanced Renal Cell Carcinoma drugs, inactive and dormant assets, a comprehensive assessment of driving and restraining factors, and an assessment of opportunities and risks in the Advanced Renal Cell Carcinoma clinical trial landscape.
Advanced Renal Cell Carcinoma Overview
According to the Centers for Disease Control and Prevention (CDC) Trusted Source, Renal Cell Carcinoma (RCC) is the most common type of kidney cancer. This type of cancer develops in the lining of very small tubes, or tubules, inside the kidney. These tubules help to remove waste products from the blood.
Find out more about Advanced Renal Cell Carcinoma Treatment Landscape @ Drugs for Advanced Renal Cell Carcinoma Treatment
Advanced Renal Cell Carcinoma Emerging Drugs Profile
- Belzutifan: Merck Sharp & Dohme
- IPI-549: Infinity Pharmaceuticals
- JANX008: Janux Therapeutics
Advanced Renal Cell Carcinoma Pipeline Therapeutics Assessment
There are approx. 50+ key companies which are developing the therapies for Advanced Renal Cell Carcinoma. The Advanced Renal Cell Carcinoma companies which have their Advanced Renal Cell Carcinoma drug candidates in the most advanced stage, i.e. phase III include, Merck Sharp & Dohme.
DelveInsight’s Advanced Renal Cell Carcinoma pipeline report covers around 60+ products under different phases of clinical development like
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
Advanced Renal Cell Carcinoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
- Oral
- Intravenous
- Subcutaneous
- Parenteral
- Topical
Products have been categorized under various Molecule types such as
- Recombinant fusion proteins
- Small molecule
- Monoclonal antibody
- Peptide
- Polymer
- Gene therapy
Learn more about the emerging Advanced Renal Cell Carcinoma Pipeline Therapies @ Advanced Renal Cell Carcinoma Clinical Trials Assessment
Scope of the Advanced Renal Cell Carcinoma Pipeline Report
- Coverage- Global
- Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
- Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
- Advanced Renal Cell Carcinoma Companies– Merck Sharp & Dohme, Chia Tai Tianqing Pharmaceutical, Hoffmann-La Roche, CoImmune, Infinity Pharmaceuticals, NiKang Therapeutics, Molecure S.A., Daiichi Sankyo, Janux Therapeutics, MedImmune, Eli Lilly and Company, Jiangsu HengRui Medicine Co., Ltd., Allogene Therapeutics, Chongqing Precision Biotech Co., Ltd, Pfizer, Exelixis, BeiGene, Xencor, and others.
- Advanced Renal Cell Carcinoma Pipeline Therapies– ABT-869, MEDI5752, Axitinib, Lenvatinib, CMN-001, Cabozantinib, Sorafenib, Tivozanib (AV-951), and others
Dive deep into rich insights for new drugs for Advanced Renal Cell Carcinoma Treatment, Visit @ Advanced Renal Cell Carcinoma Market Drivers and Barriers, and Future Perspective
Table of Content
- Introduction
- Executive Summary
- Advanced Renal Cell Carcinoma: Overview
- Pipeline Therapeutics
- Therapeutic Assessment
- Advanced Renal Cell Carcinoma– DelveInsight’s Analytical Perspective
- Late Stage Products (Phase III)
- Belzutifan: Merck Sharp & Dohme
- Drug profiles in the detailed report…..
- Mid Stage Products (Phase II)
- IPI-549: Infinity Pharmaceuticals
- Drug profiles in the detailed report…..
- Early Stage Products (Phase I)
- JANX008: Janux Therapeutics
- Drug profiles in the detailed report…..
- Preclinical and Discovery Stage Products
- Drug Name: Company Name
- Drug profiles in the detailed report…..
- Inactive Products
- Advanced Renal Cell Carcinoma Key Companies
- Advanced Renal Cell Carcinoma Key Products
- Advanced Renal Cell Carcinoma- Unmet Needs
- Advanced Renal Cell Carcinoma- Market Drivers and Barriers
- Advanced Renal Cell Carcinoma- Future Perspectives and Conclusion
- Advanced Renal Cell Carcinoma Analyst Views
- Advanced Renal Cell Carcinoma Key Companies
- Appendix
For further information on the Advanced Renal Cell Carcinoma Pipeline therapeutics, reach out to Advanced Renal Cell Carcinoma Unmet Needs and Analyst Views
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: +91-9650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/behcets-disease-market